Bowel cancer “melted away” after immunotherapy, then stayed away

A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy. After nearly three years of follow-up, none of the patients had experienced a cancer recurrence, including those who still had small traces of disease after treatment.

More in Research

Mysterious brain activity under anesthesia challenges what we know about consciousness October 15, 2026 Arctic sea ice hits another troubling low in 2026 October 15, 2026 Eating late at night linked to up to 30% higher risk of liver disease October 15, 2026 A fungus is threatening the world’s food supply. Scientists just found a new defense October 15, 2026 Scientists discover a surprising danger in smaller cancer cells October 15, 2026 Rare study reveals a striking divide inside an Alzheimer’s patient’s brain October 15, 2026

See all 66 in Research →